Rimon Therapeutics :: Part one of a two part interview with Dr. Michael H. May PhD, President, Director, Rimon Therapeutics at BioFinance 2007

Main Page

Rimon Team

Conferences, Presentations and Posters

Technologies and Products

Markets and Opportunities

Media Kit

Photos

Rimon’s Holiday Lunch, 2008

HTX HealthTechnologyExchange

This Month

Month Archive

July 2007
May 2007
April 2007
March 2007
February 2007

Year Archive

2009
2008
2007
2006

Contact Information:

For More Information Contact: Rimon Therapeutics Limited 59 Adelaide St. East Suite 500 Toronto, Ontario Canada, M5C 1K6, 416-977-2003 (office), 416-977-6383 (fax), info@rimontherapeutics.com (email) or visit our website at: www.rimontherapeutics.com

Media Contact: Howard Oliver, What If What Next, 416-638-8582, holiver@whatifwhatnext.com.

Main Page

Previous:	Interview with Gary Skarja, PhD., Director, R&D
Next:	Part two of a two part interview with Dr. Michael H. May PhD, President, Director, Rimon Therapeutics at BioFinance 2007

Part one of a two part interview with Dr. Michael H. May PhD, President, Director, Rimon Therapeutics at BioFinance 2007

by Howard on Mon 30 Apr 2007 11:40 AM EDT | Permanent Link | Cosmos

BioFinance 2007 is the Canadian Life Science industry's leading investor conference. Each year the meeting brings together key industry players to consider investment opportunities and issues affecting companies in biotechnology, medical devices, diagnostics and research tools.

Participants include senior life science executives, institutional and venture capital investors, industry analysts, corporate finance executives and experts from the scientific and medical communities in Canada, the United States, Europe and Asia. BioFinance 2007 was held on April 24 - 26, 2007 at the Toronto Marriott Eaton Centre. Rimon Therapeutics was one of 100 life sciences companies from Canada, United States and Europe that presented at BioFinance 2007. Howard Oliver spoke to Dr. Michael H. May PhD, President, Director, Rimon Therapeutics after his presentation at the event.

Howard: Each participating company has the opportunity to present their story for half-an- hour. What was the emphasis of your presentation this year?

Mike: My intent was to communicate the progress we have made, particularly with the clinical trial of MI-Sorb™ Dressing for chronic wounds. We had significant scientific progress to report from the clinical trial. We also discussed how that data has impacted our partnership discussions and advancement of pipeline products as well.

Howard: Who came to your presentation?

Mike: We had a full room. I was pleased with the turnout. There were some representatives of wound care companies. There were also the regular people who come to keep track of what we are doing and get an update on our progress. It was gratifying to have our progress acknowledged.

Howard: After BioFinance, what events are you going to be participating in?

Mike: Three or four of the Rimon team are going to a combined conference of the Symposium of Advanced Wound Care and the Annual Wound Care Society Meeting in Tampa, Florida. We have two oral presentations, one on the SAWC side and the other on the wound healing side. There are few oral presentations given at the Symposium. It is a credit to our process and the novelty of our products that we were invited to present. It is an unusual opportunity to present our clinical detail in some detail, much more than I presented at my presentation today at BioFinance. We will delve into the technical aspects of the product and its design.

Keywords: BioFinance2007, BioFinance, TheramerTM, RimonTherapeuticsLtd, rimontherapeutics, MISorb, michaelmay

Posted to:

Main Page